- 专利标题: Respiratory syncytial virus (RSV) vaccine
-
申请号: US18463276申请日: 2023-09-07
-
公开(公告)号: US11965000B2公开(公告)日: 2024-04-23
- 发明人: Thomas Kramps , Margit Schnee , Daniel Voss , Benjamin Petsch
- 申请人: CureVac SE
- 申请人地址: DE Tübingen
- 专利权人: CureVac SE
- 当前专利权人: CureVac SE
- 当前专利权人地址: DE Tübingen
- 代理机构: Parker Highlander PLLC
- 分案原申请号: US17316834 2021.05.11
- 主分类号: C07K14/005
- IPC分类号: C07K14/005 ; A61K39/12 ; A61K39/155 ; C07K16/10 ; C12N7/00 ; A61K39/00 ; A61K48/00
摘要:
The present invention relates to an mRNA sequence, comprising a coding region, encoding at least one antigenic peptide or protein of RSV infections Respiratory syncytial virus (RSV) or a fragment, variant or derivative thereof. Additionally the present invention relates to a composition comprising a plurality of mRNA sequences comprising a coding region, encoding at least one antigenic peptide or protein of RSV infections Respiratory syncytial virus (RSV) or a fragment, variant or derivative thereof. Furthermore it also discloses the use of the mRNA sequence or the composition comprising a plurality of mRNA sequences for the preparation of a pharmaceutical composition, especially a vaccine, e.g. for use in the prophylaxis or treatment of RSV infections Respiratory syncytial virus (RSV) infections. The present invention further describes a method of treatment or prophylaxis of RSV infections using the mRNA sequence.
公开/授权文献
- US20240002449A1 RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE 公开/授权日:2024-01-04
信息查询